Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial
Authors' conclusion
Protein signatures dominated by acute-phase proteins define progression to RA, whereas changes associated with abatacept therapy highlight potential mechanisms of treatment response.
Study context
- Population
- At-risk individuals in the APIPPRA (Arthritis Prevention In the Preclinical Phase of rheumatoid arthritis (RA) with Abatacept) study440 serum samples
- Participants
- 118 individuals
- Comparison
- Progressors of RA vs nonprogressors; abatacept vs placebo
- Progressorsn = 46
- Nonprogressorsn = 72reference
- Primary endpoint
- Serum protein signatures associated with progression to RA and response to abatacept
Methodological detailsserum proteomics (SomaScan 7k assay platform), prespecified subpanels: Inflammatory Mediators and Adaptive Immune Cell panel
- Serum proteomics (SomaScan 7k assay platform)
- Prespecified subpanels: Inflammatory Mediators and Adaptive Immune Cell panel
Primary result
As reported in the abstract
Significant changes in proteins between RA onset and 6 to 24 months before developing disease (68 down-regulated, 12 up-regulated)
80
Abatacept vs placebo, regardless of RA outcome: up-regulated proteins (CTLA4, CD86)
2
Abatacept vs placebo, regardless of RA outcome: down-regulated proteins (CXCL13, FCRL4, FCER2, CCL21, LTA|LTB, FDCSP, IL22RA2)
7
Original publication
Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial. Arthritis Rheumatol. Published 17 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →